KYORIN Pharmaceutical パチスロ検定通過., Ltd.

パチスロ検定通過
Contact Us
Sitemap

日本語
English

Site Search

About パチスロ検定通過
About パチスロ検定通過
KYORIN Holdings, Inc. has merged its wholly owned subsidiary KYORIN Pharmaceutical. パチスロ検定通過., Ltd and has changed its trade name to “KYORIN Pharmaceutical. パチスロ検定通過., Ltd.” on April 2023.
Investor Relations
Investor Relations
This section provides information on the Long-term vision, medium-term business plan, financial and performance results, IR library and stock.
Sustainability
Sustainability
Following our corperate philosophy, パチスロ検定通過 Group is working to contribute to society’s continuous development and our sustainable growth by fulfilling our social responsibility through we business activities with new drug as our core business.
R&D
R&D
A large number of unmet medical needs are still present in the world. This section provides information on our initiatives for drug discovery, and development pipeline.

Site Search

日本語
English

KYORIN Pharmaceutical パチスロ検定通過., Ltd.

About パチスロ検定通過

Investor Relations

Sustainability

R&D

パチスロ検定通過 Release
Contact Us
Site Map

パチスロ検定通過

Top
パチスロ検定通過
パチスロ検定通過

パチスロ検定通過

May 11, 2023

Please see the PDF file below for details.

パチスロ検定通過 [ 52.1 KB ]

Previous Article
Next Article

Archive

2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006

Go to page top Top

KYORIN Pharmaceutical パチスロ検定通過., Ltd.Top

About パチスロ検定通過

Investor Relations

Sustainability

R&D

Handling of personal information
Terms and conditions
Social Media Policy
Recommended environment / Web accessibility

©2023 KYORIN Pharmaceutical パチスロ検定通過., Ltd. All Rights Reserved.